Indefinite Delivery Contract W81K0225DA024

Roche Diagnostics Corporation was awarded a single-award Indefinite Delivery Contract by the Defense Health Agency with a ceiling value of $215,748.90, effective from October 1, 2025, through September 30, 2028. The contract, issued without set-aside designation, provides blood gas reagents, supplies, maintenance, and training services for Madigan Army Medical Center in Tacoma, Washington. This indefinite delivery vehicle serves as the parent contract mechanism enabling the government to issue delivery orders for diagnostic support services on an as-needed basis throughout the three-year ordering period. Roche Diagnostics Corporation, a foreign-owned manufacturer of in vitro diagnostic products and laboratory instruments, is a global leader in providing diagnostic solutions to military and civilian healthcare systems and was selected as the sole-source contractor based on proprietary compatibility requirements with existing government-owned equipment.

The original solicitation, issued by the Department of the Army Medical Command's Medical Readiness Contracting Office - Pacific on September 2, 2025, justified sole-source procurement based on market research demonstrating that Roche Diagnostics Corporation was the only vendor capable of supplying required proprietary reagents and support services for two existing B221 Blood Gas Analyzer systems located within the medical center's pathology department. A firm fixed-price delivery order issued concurrently on October 1, 2025, valued at $71,916.30 with performance through September 30, 2026, represents the initial task order under this indefinite delivery contract. The contracted deliverables include blood gas testing reagents, consumable supplies, equipment maintenance services, and technical training to ensure sustained laboratory operational capability and clinical diagnostic support for military healthcare delivery at Madigan Army Medical Center.